CHARLESTON, S.C., Jan. 31, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP) announces a major breakthrough in automatic retractable prefilled safety syringe technology. Building on the Company's proprietary vacuum based technology, important improvements in performance have been made that will set a new gold standard for safety in automatic prefilled syringes. The enhanced technology will provide for a level of passive protection from needle stick injury that is unmatched in the industry. Because of the small number of parts, longer shelf life, and elegance of the vacuum design, the price point will be far below that of any competitive prefilled safety syringe technology currently on the market.
"Our new prefilled auto retractable vacuum safety syringe designs will allow us to compete in another part of the market that has tremendous growth. We will be filing additional patents shortly to protect and expand our new prefilled syringe technologies. There is potential to form strategic partnerships with one or more pharmaceutical companies to provide a better prefilled syringe to deliver their products than currently exists," states Ron Wheet, CEO of Revolutions Medical.
Almost 50 injectable drug products are currently supplied in prefilled syringes. Combined, these drugs achieved annual sales of approximately $45 billion in 2007. Prefilled syringes offer significant financial and industrial benefits to pharmaceutical companies in areas such as reduced dose wastage and improved drug marketability to healthcare workers, and patients who self-administer prescribed medication at home. Due to such growth drivers, we expect that more than 3 billion prefilled syringes will be manufactured globally in 2011.
The company is still on schedule to ship its first 3ml RevVac fixed needle safety syringes in April and its first 1ml RevVac fixed needle safety syringes in July 2011 from its manufacturer in China. Revolutions Medical will have final production samples and take its first orders from distributors by mid-March.
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved), safety blood drawing device; and the RevColorTM, RevDisplayTM and Rev3DTM software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS) preliminary called RevTrack (FDA approved).
For additional information, please visit Revolutions Medical corporate website: http://www.revolutionsmedical.com
To listen to a recent interview by Wall Street Reporter use the link provided below:
http://www.wallstreetreporter.com/2011/01/revolutions-medical-otcbbrmcp-ceo-interview/
To be added to the Revolutions Medical investor email list, please email investment@revolutionsmedical.com with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook -- visit www.Facebook.com/Revmed" target="_top" rel="nofollow">http://www.Facebook.com/Revmed
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.